Comparison · NCT01178086-sae
Unselected Population (Participants With Any Comorbidity) vs Slow Go Subpopulation: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Unselected Population (Participants With Any Comorbidity) vs Slow Go Subpopulation: serious adverse events. Trial comparisons, record NCT01178086-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01178086-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.175 | 0.144 | 0.212 | wilson | |
| Risk in group 2 | 0.224 | 0.172 | 0.288 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0492 | -0.12 | 0.0149 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.781 | 0.565 | 1.08 | log | |
| Odds ratio, group 1 over group 2 | 0.734 | 0.488 | 1.11 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Unselected Population (Participants With Any Comorbidity) than on Slow Go Subpopulation | 20.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Unselected Population (Participants With Any Comorbidity) | Unselected population (participants with any comorbidity) who were treated with IV rituximab in combination with chemotherapy, were observed for 24 months including 6-month treatment period. | 85 | 485 | EG000 |
| Group 2 | Slow Go Subpopulation | Slow go subpopulation (participants with CIRS-G score \>6 and/or creatinine clearance \<70 mL/min) who were treated with IV rituximab in combination with chemotherapy, were observed for 24 months including 6-month treatment period. | 44 | 196 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline up to 24 months
Source ClinicalTrials.gov
Trial
- Title
- A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)
- NCT number
- NCT01178086
- Phases
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- Rituximab
- Lead sponsor
- Hoffmann-La Roche
- Results first posted
- 2018-10-05
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01178086?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01178086-sae